In older transgenic animals (12 months), the MSC or MSC-VEGF treatments were able to keep the astrocytic activation levels similar to those found in the age-matched wild type animals, but did not reduce the number of astrocytes compared to the transgenic AD non-treated levels. Here, VEGFA is linked to Alzheimer disease.